UNSPSC 51142566: Pramipexole hydrochloride hydrate

This classification denotes an antidepressant agent with the molecular formula C10H17N3S.2ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3D867NP06J, chemically known as (s)-2-amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole dihydrochloride monohydrate, but more generally known as pramipexole hydrochloride hydrate, which bears US NIH Compound Identifier 166589.

European Medicines Agency schedules pramipexole hydrochloride hydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09990MIG. Most nations, for tariff purposes, schedule pramipexole hydrochloride hydrate under HS 29341000. SMILES: CCCN[C@H]1CCC2C(SC(N2)N)C1.O.CL.CL.

UNSPSC 51142566 Pramipexole hydrochloride hydrate is a Commodity code, yet the three recent state and local opportunities posted under it show limited direct relevance to this specific pharmaceutical product. The code nominally describes a dopamine agonist medication used to treat Parkinson's disease and restless leg syndrome, but the recent solicitations indexed to it instead cover naloxone procurement, direct-to-manufacturer pharmacy programs, and multi-source generic pharmaceutical supply agreements—none of which specifically target pramipexole. The scope mismatch suggests either indexing inconsistency within state and local procurement systems or that this code is cast broadly enough to capture various pharmaceutical supply and delivery models. When opportunities do align with pharmaceutical procurement under broader codes, state and local buyers are seeking either emergency-response products (naloxone), strategic sourcing arrangements with manufacturers to bypass traditional pharmacy benefit manager channels, or volume supply of established generic medications through cooperative purchasing frameworks.

Recent activity spans Florida, Texas, and Minnesota through county health departments, state health and human services commissions, and multi-state cooperative purchasing alliances. Seminole County, Florida issued IFB 60459723LAS (closed July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, structured as a two-year initial contract with one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 (April 3, 2026) to explore direct-to-manufacturer prescription fulfillment models outside traditional pharmacy benefit managers and group purchasing organizations. The Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers, with contract awards effective July 1, 2026 and pricing weighted 75 percent on competitiveness. The geographic and issuing-body mix suggests pharmaceutical procurement under this code operates across state departments, counties, and regional cooperative purchasing vehicles, though the specific indexing of pramipexole remains unclear from current activity.